Washington, DC  20549






Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of Report (Date of earliest event Reported):  November 27, 2012




(Exact Name of Registrant as Specified in its Charter)




(State or Other Jurisdiction of



(Commission File Number)



(I.R.S. Employer Identification Number)


901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 7.01 Regulation FD Disclosure.


The information contained in this Item 7.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.


Today Michael W. Aguiar, Senior Vice President and Chief Financial Officer of Theravance, Inc. (the “Company”) presented at the Piper Jaffray Healthcare Conference in New York, New York.  During the fireside chat style presentation, Mr. Aguiar announced that GlaxoSmithKline plc (GSK) and the Company have decided to advance GSK961081 (‘081) monotherapy to Phase 3 in the course of 2013.  ‘081 is an investigational, single molecule bifunctional bronchodilator with both muscarinic antagonist and beta2 receptor agonist activities for the treatment of chronic obstructive pulmonary disease (COPD).  In addition, GSK and the Company plan to progress the combination of ‘081 and fluticasone furoate (FF), an investigational once-daily inhaled corticosteroid, into Phase 3-enabling studies shortly.  ‘081 is in development under the strategic alliance between GSK and the Company.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.







Date: November 27, 2012


/s/ Michael W. Aguiar



Michael W. Aguiar



Chief Financial Officer